---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-029936"
form_type: "8-K"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2024-09-25T23:59:59+00:00"
generated_at: "2026-05-31T01:58:35.370849+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "medium"
source: SEC EDGAR
---

# Windtree announces positive Phase 2b topline results for istaroxime in early cardiogenic shock

## Summary
- Istaroxime met primary endpoint: significantly improved systolic blood pressure profile over six hours vs placebo.
- Significant improvements in many secondary endpoints; safety profile favorable, consistent with prior trials.
- Study tested two dosing regimens (decreasing and constant) over up to 60 hours infusion to optimize late-stage design.
- Detailed results to be presented at Heart Failure Society of America on Sept 30, 2024; investor call planned.

## SEC filing metadata
- accession: 0001437749-24-029936
- form_type: 8-K
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2024-09-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774924029936/0001437749-24-029936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774924029936/wint20240924c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-029936
- JSON: https://secwatch.observer/filing/0001437749-24-029936.json
- Plain text: https://secwatch.observer/filing/0001437749-24-029936.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.